糖皮质激素单药对比联合内镜胆道引流治疗自身免疫性胰腺炎伴显著梗阻性黄疸:多中心开放标签非劣效随机对照试验方案
本研究为多中心、开放标签、非劣效随机对照试验,计划纳入78例伴显著梗阻性黄疸(总胆红素≥3倍正常上限)且无胆管炎的自身免疫性胰腺炎患者,随机接受内镜逆行胆道引流联合糖皮质激素或糖皮质激素单药治疗。主要终点为干预2周内总胆红素下降≥50%的临床应答率,旨在验证糖皮质激素单药是否非劣效于联合引流。
要点
- 糖皮质激素单药可能非劣效于ERBD联合激素治疗AIP伴显著梗阻性黄疸。
- 主要终点为2周内总胆红素下降≥50%的临床应答率。
- 纳入标准为总胆红素≥3倍正常上限且无胆管炎。
核心结论
- 本试验旨在确定糖皮质激素单药作为初始治疗是否非劣效于ERBD联合糖皮质激素用于AIP伴显著梗阻性黄疸患者。
研究设计与样本
- 多中心、非劣效、开放标签、随机对照试验,计划在中国13个中心纳入78例患者,每组39例。
关键数值与推荐
- 纳入标准:显著梗阻性黄疸定义为血清总胆红素≥3倍正常上限,且无并发胆管炎。
- 主要终点:临床应答率,定义为干预2周内总胆红素水平下降≥50%。
- 次要终点:不良事件发生率,包括ERCP相关并发症和糖皮质激素相关不良事件。
临床怎么用
- 本试验结果将为AIP伴显著梗阻性黄疸患者是否需要常规在激素治疗前进行ERBD提供随机对照证据,辅助临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with autoimmune pancreatitis (AIP) frequently develop obstructive jaundice. Endoscopic retrograde biliary drainage (ERBD) is typically performed before glucocorticoid initiation to prevent biliary infections and worsening cholestasis. While guidelines support glucocorticoid monotherapy without ERBD for mild jaundice, its efficacy and safety remain unestablished in AIP patients with clinically significant obstructive jaundice. This trial aims to determine whether glucocorticoid monotherapy is noninferior to ERBD plus glucocorticoids as initial therapy for AIP patients with significant obstructive jaundice. METHODS/DESIGN: In this multicenter, noninferiority, open-label, randomized controlled trial, 78 patients with significant obstructive jaundice without concurrent cholangitis (serum total bilirubin ≥ 3 × ULN) across 13 centers in China will be randomly assigned to receive either ERBD plus glucocorticoids or glucocorticoids alone (39 patients per group). The primary endpoint is the clinical response rate, which was defined as a ≥ 50% reduction in the total bilirubin level within 2 weeks of the intervention. The secondary outcomes are adverse event rates, including ERCP-related complications and glucocorticoid-related adverse events. DISCUSSION: This trial is expected to reveal whether ERBD is routinely required before glucocorticoid administration in AIP patients with significant obstructive jaundice, which is an important question that has not been addressed via an RCT design. The results will supplement the evidence for clinical decision-making and may provide a more straightforward basis for treatment selection, potentially simplifying the management of these patients. TRIAL REGISTRATION: Chictr.org.cn ChiCTR2400086160. Registered on June 26, 2024.
引用
- Chen S, Liang Y, Chen D, et al. Endoscopic retrograde biliary drainage plus glucocorticoids versus glucocorticoid alone for autoimmune pancreatitis with significant obstructive jaundice: study protocol for a multicenter, open-label, non-inferiority randomized controlled trial. Trials. 2026. PMID: 41782034. doi:10.1186/s13063-026-09595-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。